Scientists identify dangerous amount of methamphetamine analog in workout supplement Craze

An international team of scientists have identified potentially dangerous amounts of methamphetamine analog in the workout supplement Craze, a product widely sold across the U.S. and online. The study, published in Drug Testing and Analysis, was prompted by a spate of failed athletic drug tests. The results reveal the presence of methamphetamine analog N,α- DEPEA, which has not been safely tested for human consumption, in three samples.

"In recent years banned and untested drugs have been found in hundreds of dietary supplements. We began our study of Craze after several athletes failed urine drug tests because of a new methamphetamine analog," said lead author Dr. Pieter Cohen, of Harvard Medical School, U.S.A.

A workout supplement marketed as a 'performance fuel', Craze is manufactured by Driven Sports, Inc. It is sold in stores across the United States and internationally via body supplement websites.

The supplement is labeled as containing the compound N,N-diethyl-phenylethylamine (N,N-DEPEA), claiming it is derived from endangered dendrobium orchids. However, while there is no proof that this compound is found within orchids, it is also structurally similar to the methamphetamine analog N,α-diethylphenylethylamine (N,α-DEPEA), a banned substance.

The team analyzed three samples of Craze for traces of N,α-DEPEA. The first sample was brought from a mainstream retailer in the U.S., while the second and third samples were ordered from online retailers in the U.S. and Holland.

The team used ultra-high performance liquid chromatography to detect the presence of N,α-DEPEA. The first two samples were analyzed by NSF International, while the third was tested at the Netherland's National Institute for Public Health. The findings were independently corroborated by the Korean Forensic Service, which confirmed the presence of N,α-DEPEA in two further samples of Craze in a parallel investigation.

"We identified a potentially dangerous designer drug in three separate samples of this widely available dietary supplement," said Cohen. "The tests revealed quantities of N,α-DEPEA of over 20mg per serving, which strongly suggests that this is not an accidental contamination from the manufacturing process."

As a structural analog of methamphetamine, N,α-DEPEA , may have stimulant and addictive qualities; however, it has never been studied in humans and its adverse effects remain unknown.

The product labeling claims that Craze contains several organic compounds, known as phenylethylamines. However, phenylethylamines are a very broad category of chemicals which range from harmless compounds found in chocolate to synthetically produced illegal drugs.

"The phenylethylamine we identified in Craze, N,α-DEPEA, is not listed on the labeling and it has not been previously identified as a derivative of dendrobium orchids," said Cohen.

"If these findings are confirmed by regulatory authorities, the FDA (The U.S. Food and Drug Administration) must take action to warn consumers and to remove supplements containing N,α-DEPEA from sale," concluded Cohen. "Our fear is that the federal shutdown may delay this, resulting in potentially dangerous supplements remaining widely available."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials